Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myanmar malaria therapeutic efficacy study
ACTRN12611001246976Phase 4Not yet recruiting
- Sponsor
- Defense Services General Hospital
- Start
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of artemether + lumefantrine, artesunate + mefloquine and chloroquine in malaria and Malaria (3 arms), sponsored by Defense Services General Hospital. Primary endpoints: Treatment failure rate and Adverse event rate. Planned start Jan 2012; status: not yet recruiting.
02
Drugs
artemether + lumefantrineartesunate + mefloquinechloroquine
03
Conditions
malariaMalaria
Beyond the preview
Go deeper on ACTRN12611001246976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611001246976.